Abstract
dc:descriptionBackground-Purpose: PCSK9 is a serine protease which, in addition to its major role in endosomal and lysosomal degradation of the LDL receptor, which results in increased plasma LDL-cholesterol levels, exhibits several LDL receptor-independent actions on a variety of cell types, including platelets. Recent studies have demonstrated that PCSK9 is involved in the pathophysiology of inflammation and shows actions on other cell types, such as platelets, monocytes, etc. Materials-Methods: Initially, the interaction of PCSK9 with plasma lipoproteins was studied by isolating them by sequential ultracentrifugation and determining their PCSK9 levels by ELISA. At the same time, we studied the distribution of PCSK9 in HDL lipoprotein particles by the Lipoprint system and the form of PCSK9 present in each lipoprotein was determined by the Western blotting method. To investigate the effect of PCSK9 on thrombosis, we determined the levels of endogenous PCSK9 in washed platelets isolated from normolipidemic donors and also determined in washed platelets from hypercholesterolemic patients receiving monoclonal antibody against PCSK9. The effect of recombinant PCSK9 was studied both on the accumulation of washed platelets and on endothelial function in HUVECs endothelial cells in terms of membrane expression of ICAM-1 and secretion of MCP-1. In the above systems, the effect of bound PCSK9 on LDL and HDL lipoprotein was also studied using an antibody against PCSK9. To investigate possible pleiotropic actions of monoclonal antibodies administered against PCSK9, platelet aggregation of hypercholesterolemic patients in both PRP and washed platelets was studied before and after 4 doses of the antibody. In addition, in the PRP of the patients we determined the membrane expression of P-selectin and CD40L at the above two time points. We then determined in these patients the interactions of platelets with CD34+ precursor cells in whole blood by flow cytometry. Finally, we investigated the ability of both recombinant and HDL- and LDL-associated PCSK9 to angiogenesis through lumen formation in HUVECs cells.Results: Ultracentrifugally isolated lipoproteins contain PCSK9, indicating that due to ultracentrifugation a portion of PCSK9 is uncoupled from the lipoprotein particles. The distribution in HDL particles showed that S-HDL possesses more PCSK9 while in HDL both forms of PCSK9 (mature and furin-cleaved form) are present. The washed platelets of both patients and normolipidemics contain both forms of PCSK9 while endogenous PCSK9 does not affect platelet aggregation. Recombinant PCSK9 enhances platelet aggregation induced by thrombin and arachidonic acid while alone does not induce platelet aggregation. Also, LDL and HDL inhibit platelet aggregation. In addition, monoclonal antibodies against PCSK9 in patients receiving them did not statistically significantly modify platelet aggregation before and after the antibody in both PRP and washed platelets, as well as membrane expression of P-selectin and CD40L. However, washed platelets after antibody administration contain more PCSK9. In addition, in HUVECs endothelial cells PCSK9 enhances TNF-α-induced membrane expression of ICAM-1 as well as MCP-1 secretion. In parallel, LDL and HDL inhibited the membrane expression of ICAM-1 while in the presence of an antibody against PCSK9 this inhibition was statistical significantly reduced suggesting the involvement of PCSK9 of lipoproteins in this, whereas with respect to MCP-1 lipoproteins induced its secretion. Furthermore, recombinant PCSK9 enhanced lumen formation whereas HDL and LDL inhibited VEGF-induced lumen formation. Finally, in patients under monoclonal antibodies against PCSK9 there was an increase in the endothelial phenotype of CD34+ precursor cells and platelet interactions with CD34+ precursor cells. Conclusions: This PhD thesis shows that PCSK9 in addition to its classical role in LDL receptor degradation and LDL cholesterol increase in plasma, is involved in various mechanisms of atherothrombosis such as platelet aggregation, membrane expression of the adhesion molecule ICAM-1 and secretion of MCP-1, functions that demonstrate its contribution to thrombosis and inflammation, while it also displays angiogenic actions contributing to endothelial regeneration. Also, due to the lipoprotein particles containing PCSK9, the involvement of PCSK9 in atherosclerosis is also shown. In addition, our work demonstrated that monoclonal antibodies against PCSK9, in addition to their main role, are involved in the platelet functionality of patients and more fundamentally in the endothelial phenotype of CD34+ cells and their interactions with platelets.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsouka, Aikaterini
- Τσούκα, Αικατερίνη
Subjects
dc:subject × 31- Αθηροσκλήρωση
- Αθηροθρόμβωση
- PCSK9
- Ανθρώπινα ενδοθηλιακά κύτταρα ομφάλιου λώρου
- Αιμοπετάλια
- Υψηλής πυκνότητας λιποπρωτεΐνη
- Χαμηλής πυκνότητας λιποπρωτεΐνη
- Υπερχοληστερολαιμία
- Μονοκλωνικά αντισώματα έναντι της PCSK9
- Φλεγμονή
- Atherosclerosis
- Atherothrombosis
- Human umbilical vein endothelial cells
- Platelets
- High density lipoprotein (HDL)
- Low density lipoprotein (LDL)
- Hypercholesterolaemia
- Monoclonal antibodies against PCSK9
- Inflammation
- Χημεία
- Φυσικές Επιστήμες
- Χημεία, άλλοι τομείς
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ιατρική βιοχημεία
- Chemical Sciences
- Natural Sciences
- Chemistry, miscellaneous
- Basic Medicine
- Medical and Health Sciences
- Medical Biochemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54245